Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Polaryx Therapeutics Q3 2026 Results: Net Loss of $3.33M, Loss Widens

Polaryx Therapeutics reported a net loss of $7.3 million for the nine months ended September 30, 2026, compared to $7.5 million in the prior year period. The company maintains a going concern warning due to recurring losses and negative operating cash flows, though it successfully raised $9.8 million through common stock issuances during the period.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-3.3-1.4
EPS (diluted, $ a share)$-0.07$-0.03

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: PLYX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Polaryx Therapeutics, Inc.: key numbers

Share price
$1.67Close, Nov 16
Market cap
$83.2M
Shares outstanding
49.85MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Polaryx Therapeutics, Inc.

All →
6:02 AM ET 8-K
Shareholder Meeting

Polaryx Therapeutics Shareholder Meeting

Polaryx Therapeutics held its Annual Meeting of Stockholders on September 10, 2026, where shareholders elected Alex Yang and Mitchel Berger as Class I Directors to serve until 2029. Additionally, the appointment of Grant Thornton LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.